Back to all studies
RecruitingNCT05648591

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.

SchizophreniaDrugFrom 12 Years to 17 Years
In plain English

Key information made simple

This study is looking at care and outcomes for people with Schizophrenia or Bipolarity I. Taking part may give some people access to Iloperidone, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a research setting, with sites including Vanda Investigational Site in Little Rock, Vanda Investigational Site in Denver, and Vanda Investigational Site in Atlanta. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Public study data

Key study information

Official title
Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder
Condition
Schizophrenia; Bipolar I Disorder
Study status
Recruiting
Phase
Phase 4
Sponsor / lead affiliation
Vanda Pharmaceuticals
Intervention
Iloperidone
Location / country
United States
Contact
Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals
Email
clinicaltrials@vandapharma.com
Phone
202-734-3400
Registry
ClinicalTrials.gov
Why this study may matter

Why this study may matter

This study may matter because it is evaluating Iloperidone in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.

Before joining

Questions to ask before joining

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT05648591. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Vanda Pharmaceuticals
Sponsor type
Unknown or unclear
Main activity
medication or study treatment
Intervention
Iloperidone
Time commitment
long follow-up or multiple visits
Study phase
Phase 4
Enrollment
Not available
Recruitment status
Recruiting
Source
Official registry link
FAQ

Questions about this study

What is Safety and Tolerability of Open-Labeled Iloperidone in Adolescents?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Vanda Pharmaceuticals. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 4. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Safety and Tolerability of Open-Labeled. — Schizophrenia Clinical Trial | HopeStage